Will the recent publication of the MA.20 and EORTC 22922 studies in NEJM, showing no survival advantage from regional nodal irradiation in early-stage breast cancer patient following surgery, change your standard of care for these patients?  

How much will you weigh the demonstrated disease-free survival, including distant disease-free survival, in your recommendations?



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Northwestern University
Thank you for the excellent summary! Will you c...
Radiation Oncologist at Rutgers Robert Wood Johnson Medical School
I have not made the jump to node negative but woul...
Radiation Oncologist at Confluence Health
Thank you very much. Will this modify the use of C...
Radiation Oncologist at Quillen VA Medical Center
Since current practice is to get SN only, how do t...
Radiation Oncologist at Saint John Macomb-Oakland Hospital
The benefit in terms of disease-free survival on M...
Radiation Oncologist at Radiation Oncology Associates
Thank you for the excellent summary. "In the c...
Radiation Oncologist at Jacob E Locke MD PA
Any thoughts regarding the role of Oncotype and it...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Tri-Cities Cancer Center
Can you share what beam arrangement you are using ...
Radiation Oncologist at Northwestern University
When treating regional nodes, we position the pati...
Radiation Oncologist at Tri-Cities Cancer Center
Thanks. We do DIBH as well for a number of patient...
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Community Practice
Comments
Radiation Oncologist at Cleveland Clinic
I would respectfully disagree. An improvement in D...
Sign in or Register to read more